Brian David Archbold Sells 472 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB - Get Free Report) SVP Brian David Archbold sold 472 shares of the stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $97.12, for a total value of $45,840.64. Following the completion of the transaction, the senior vice president now directly owns 558 shares of the company's stock, valued at $54,192.96. This represents a 45.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Mesa Laboratories Stock Performance

Shares of Mesa Laboratories stock traded up $2.83 on Friday, reaching $95.82. 244,290 shares of the company were exchanged, compared to its average volume of 45,991. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.47 and a current ratio of 0.63. The company's 50-day moving average is $110.56 and its two-hundred day moving average is $124.85. The firm has a market cap of $523.18 million, a price-to-earnings ratio of -258.97 and a beta of 0.88. Mesa Laboratories, Inc. has a 1-year low of $83.68 and a 1-year high of $155.12.

Mesa Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 16th. Investors of record on Friday, May 30th were issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date of this dividend was Friday, May 30th. Mesa Laboratories's dividend payout ratio (DPR) is -172.97%.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Wells Fargo & Company reduced their price target on Mesa Laboratories from $120.00 to $100.00 and set an "underweight" rating for the company in a report on Friday, May 30th. Wall Street Zen cut Mesa Laboratories from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 30th.

Hedge Funds Weigh In On Mesa Laboratories

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Mesa Laboratories by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 384,613 shares of the medical instruments supplier's stock worth $45,638,000 after buying an additional 1,757 shares in the last quarter. Raymond James Financial Inc. grew its holdings in Mesa Laboratories by 6.5% in the 1st quarter. Raymond James Financial Inc. now owns 264,013 shares of the medical instruments supplier's stock worth $31,328,000 after buying an additional 16,218 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in Mesa Laboratories by 191.8% in the 4th quarter. Ameriprise Financial Inc. now owns 151,862 shares of the medical instruments supplier's stock worth $20,026,000 after buying an additional 99,819 shares in the last quarter. Northern Trust Corp grew its holdings in Mesa Laboratories by 2.0% in the 4th quarter. Northern Trust Corp now owns 93,789 shares of the medical instruments supplier's stock worth $12,368,000 after buying an additional 1,825 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in Mesa Laboratories by 10.3% during the 4th quarter. Janus Henderson Group PLC now owns 86,286 shares of the medical instruments supplier's stock valued at $11,379,000 after purchasing an additional 8,092 shares in the last quarter. 90.60% of the stock is owned by institutional investors.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.